[COVID-19 vaccination for people with severe mental diseases : Results of the COVID Ψ outpatient survey and recommendations for psychiatry].
COVID-19-Impfung für Menschen mit schweren psychischen Erkrankungen : Ergebnisse des COVID-Ψ-Ambulant-Surveys und Empfehlungen für die Psychiatrie.
COVID-19
COVID-19 vaccination
SARS-CoV‑2 infection
Severe mental illness
Vaccination preparedness
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
13
03
2023
medline:
30
6
2023
pubmed:
4
5
2023
entrez:
3
5
2023
Statut:
ppublish
Résumé
Severe mental illnesses are risk factors for SARS-CoV-2-related morbidity and mortality. Vaccination is an effective protection; therefore, high vaccination rates should be a major priority for people with mental illnesses. (1) Identification of at-risk groups for non-vaccination and structures and interventions needed for widespread vaccination among people with mental illnesses from the perspective of outpatient psychiatrists and neurologists, (2) discussion of the results in the context of the international literature and (3) recommendations derived from them. Qualitative content analysis of COVID-19 vaccination-related questions from the COVID Ψ online survey of n = 85 psychiatrists and neurologists in Germany. In the survey, people with schizophrenia, severe lack of drive, low socioeconomic status and homelessness were seen as risk groups for non-vaccination. Increased and targeted information, education, addressing and motivation and easily accessible vaccination offers by general practitioners, psychiatrists, and neurologists as well as complementary institutions were considered as important interventions. COVID-19 vaccinations as well as information, motivation and access support should be systematically offered by as many institutions of the psychiatric, psychotherapeutic and complementary care systems in Germany as possible. HINTERGRUND: Schwere psychische Erkrankungen sind Risikofaktoren für SARS-CoV-2-bezogene Morbidität und Mortalität. Impfungen stellen einen wirksamen Schutz dar, weshalb hohe Impfraten bei Menschen mit psychischen Erkrankungen eine große Priorität haben sollten. ZIELE DER ARBEIT: (1) Identifikation von Risikogruppen für Nichtimpfung und erforderliche Strukturen und Maßnahmen für eine flächendeckende Impfung bei Menschen mit psychischen Erkrankungen, aus der Perspektive ambulanter Psychiater*innen und Nervenärzt*innen, (2) Einordnung der Ergebnisse in die internationale Literatur und (3) daraus abgeleitete Empfehlungen. Qualitative Inhaltsanalyse der Fragen des COVID-Ψ-Ambulant-Onlinesurveys, welche die COVID-19-Impfungen betreffen, von n = 85 Psychiater*innen und Nervenärzt*innen in Deutschland. Im Survey wurden insbesondere Menschen mit schizophrenen Psychosen, schweren Antriebsstörungen, geringer sozialer Einbindung und Wohnungslosigkeit als Risikogruppen für eine Nichtimpfung benannt. Als Maßnahmen wurden einerseits verstärkte und gezielte Information, Aufklärung und Motivation, andererseits einfach zugängliche Impfangebote durch Hausärzt*innen, Psychiater*innen und Nervenärzt*innen sowie komplementärer Institutionen als wichtig erachtet. COVID-19-Impfungen sowie Information, Motivation und Zugangsunterstützung sollten durch möglichst viele Institutionen des psychiatrisch-psychotherapeutischen und komplementären Versorgungssystems in Deutschland systematisch angeboten werden.
Sections du résumé
BACKGROUND
BACKGROUND
Severe mental illnesses are risk factors for SARS-CoV-2-related morbidity and mortality. Vaccination is an effective protection; therefore, high vaccination rates should be a major priority for people with mental illnesses.
OBJECTIVES
OBJECTIVE
(1) Identification of at-risk groups for non-vaccination and structures and interventions needed for widespread vaccination among people with mental illnesses from the perspective of outpatient psychiatrists and neurologists, (2) discussion of the results in the context of the international literature and (3) recommendations derived from them.
MATERIAL AND METHODS
METHODS
Qualitative content analysis of COVID-19 vaccination-related questions from the COVID Ψ online survey of n = 85 psychiatrists and neurologists in Germany.
RESULTS
RESULTS
In the survey, people with schizophrenia, severe lack of drive, low socioeconomic status and homelessness were seen as risk groups for non-vaccination. Increased and targeted information, education, addressing and motivation and easily accessible vaccination offers by general practitioners, psychiatrists, and neurologists as well as complementary institutions were considered as important interventions.
DISCUSSION
CONCLUSIONS
COVID-19 vaccinations as well as information, motivation and access support should be systematically offered by as many institutions of the psychiatric, psychotherapeutic and complementary care systems in Germany as possible.
ZUSAMMENFASSUNG
UNASSIGNED
HINTERGRUND: Schwere psychische Erkrankungen sind Risikofaktoren für SARS-CoV-2-bezogene Morbidität und Mortalität. Impfungen stellen einen wirksamen Schutz dar, weshalb hohe Impfraten bei Menschen mit psychischen Erkrankungen eine große Priorität haben sollten. ZIELE DER ARBEIT: (1) Identifikation von Risikogruppen für Nichtimpfung und erforderliche Strukturen und Maßnahmen für eine flächendeckende Impfung bei Menschen mit psychischen Erkrankungen, aus der Perspektive ambulanter Psychiater*innen und Nervenärzt*innen, (2) Einordnung der Ergebnisse in die internationale Literatur und (3) daraus abgeleitete Empfehlungen.
MATERIAL UND METHODEN
METHODS
Qualitative Inhaltsanalyse der Fragen des COVID-Ψ-Ambulant-Onlinesurveys, welche die COVID-19-Impfungen betreffen, von n = 85 Psychiater*innen und Nervenärzt*innen in Deutschland.
ERGEBNISSE
UNASSIGNED
Im Survey wurden insbesondere Menschen mit schizophrenen Psychosen, schweren Antriebsstörungen, geringer sozialer Einbindung und Wohnungslosigkeit als Risikogruppen für eine Nichtimpfung benannt. Als Maßnahmen wurden einerseits verstärkte und gezielte Information, Aufklärung und Motivation, andererseits einfach zugängliche Impfangebote durch Hausärzt*innen, Psychiater*innen und Nervenärzt*innen sowie komplementärer Institutionen als wichtig erachtet.
DISKUSSION
CONCLUSIONS
COVID-19-Impfungen sowie Information, Motivation und Zugangsunterstützung sollten durch möglichst viele Institutionen des psychiatrisch-psychotherapeutischen und komplementären Versorgungssystems in Deutschland systematisch angeboten werden.
Autres résumés
Type: Publisher
(ger)
HINTERGRUND: Schwere psychische Erkrankungen sind Risikofaktoren für SARS-CoV-2-bezogene Morbidität und Mortalität. Impfungen stellen einen wirksamen Schutz dar, weshalb hohe Impfraten bei Menschen mit psychischen Erkrankungen eine große Priorität haben sollten. ZIELE DER ARBEIT: (1) Identifikation von Risikogruppen für Nichtimpfung und erforderliche Strukturen und Maßnahmen für eine flächendeckende Impfung bei Menschen mit psychischen Erkrankungen, aus der Perspektive ambulanter Psychiater*innen und Nervenärzt*innen, (2) Einordnung der Ergebnisse in die internationale Literatur und (3) daraus abgeleitete Empfehlungen.
Identifiants
pubmed: 37138091
doi: 10.1007/s00115-023-01477-5
pii: 10.1007/s00115-023-01477-5
pmc: PMC10155662
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
619-624Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Robert Koch Institut COVID-19 Fallzahlen in Deutschland. www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html . Zugegriffen: 29. Juli 2022
Qian Z, Li Z, Peng J et al (2022) Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis. Clin Exp Hypertens 44:451–458. https://doi.org/10.1080/10641963.2022.2071914
doi: 10.1080/10641963.2022.2071914
pubmed: 35531646
Khoury E, Nevitt S, Madsen WR et al (2022) Differences in outcomes and factors associated with mortality among patients with SARS-coV‑2 infection and cancer compared with those without cancer: a systematic review and meta-analysis. JAMA Netw Open 5:e2210880. https://doi.org/10.1001/jamanetworkopen.2022.10880
doi: 10.1001/jamanetworkopen.2022.10880
pubmed: 35532936
pmcid: 9086843
Shin E, Jin J, Park SY et al (2022) Impact of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap on the prognosis of coronavirus disease 2019. Asia Pac Allergy 12:e21. https://doi.org/10.5415/apallergy.2022.12.e21
doi: 10.5415/apallergy.2022.12.e21
pubmed: 35571550
pmcid: 9066077
Ekinci O, Erkan Ekinci A (2022) Demographic and clinical factors related to severe COVID-19 infection and mortality in patients with schizophrenia. J Nerv Ment Dis 210:257–263. https://doi.org/10.1097/NMD.0000000000001500
doi: 10.1097/NMD.0000000000001500
pubmed: 35212665
pmcid: 8963440
Tzur Bitan D, Kridin K, Cohen AD, Weinstein O (2021) COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study. Lancet Psychiatry 8:901–908. https://doi.org/10.1016/S2215-0366(21)00256-X
doi: 10.1016/S2215-0366(21)00256-X
pubmed: 34364406
pmcid: 8342316
Ceban F, Nogo D, Carvalho IP et al (2021) Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry 78:1079–1091. https://doi.org/10.1001/jamapsychiatry.2021.1818
doi: 10.1001/jamapsychiatry.2021.1818
pubmed: 34319365
pmcid: 8319830
Catalan A, Aymerich C, Bilbao A et al (2022) Psychosis and substance abuse increase the COVID-19 mortality risk. Psychol Med. https://doi.org/10.1017/S0033291722000976
doi: 10.1017/S0033291722000976
pubmed: 35410632
pmcid: 9114752
De Hert M, Mazereel V, Stroobants M et al (2021) COVID-19-related mortality risk in people with severe mental illness: a systematic and critical review. Front Psychiatry 12:798554. https://doi.org/10.3389/fpsyt.2021.798554
doi: 10.3389/fpsyt.2021.798554
pubmed: 35095612
Adorjan K, Haussmann R, Rauen K, Pogarell O (2021) Consequences of the COVID-19 pandemic for people with schizophrenia, dementia and substance use disorders. Nervenarzt 92:571–578. https://doi.org/10.1007/s00115-021-01105-0
doi: 10.1007/s00115-021-01105-0
pubmed: 33779773
pmcid: 8006113
Robert Koch Institut Gesundheitsberichterstattung des Bundes. Gesundheitsmonitoring „Schizophrenie“. https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsT/Schizophrenie.pdf?__blob=publicationFile . Zugegriffen: 29. Juli 2022
Informationen der Bundesregierung zu Regeln im Umgang mit COVID-19. https://www.bundesregierung.de/breg-de/themen/coronavirus/corona-bundeslaender-1745198 . Zugegriffen: 29. Juli 2022
Robert Koch Institut STIKO-Empfehlung zur COVID-19-Impfung. https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/COVID-19/Impfempfehlung-Zusfassung.html . Zugegriffen: 28. Aug. 2022
Mayring P (2014) Qualitative content analysis: theoretical foundation, basic procedures and software solution. ssoar open access repository
Arumuham A, O’Brien O, Ahmad Z et al (2022) Low COVID-19 vaccination rates in people with severe mental illness and reasons for this: An out-patient study. Acta Psychiatr Scand 145:416–418. https://doi.org/10.1111/acps.13400
doi: 10.1111/acps.13400
pubmed: 35263443
pmcid: 9111255
Goldberger N, Bergman-Levy T, Haklai Z et al (2022) COVID-19 and severe mental illness in Israel: testing, infection, hospitalization, mortality and vaccination rates in a countrywide study. Mol Psychiatry. https://doi.org/10.1038/s41380-022-01562-2
doi: 10.1038/s41380-022-01562-2
pubmed: 35459901
pmcid: 9028900
Nguyen KH, Chen S, Morris K et al (2022) Mental health symptoms and association with COVID-19 vaccination receipt and intention to vaccinate among adults, United States. Prev Med 154:106905. https://doi.org/10.1016/j.ypmed.2021.106905
doi: 10.1016/j.ypmed.2021.106905
pubmed: 34863815
Huang H, Zhu X‑M, Liang P‑W et al (2021) COVID-19 vaccine uptake, acceptance, and hesitancy among persons with mental disorders during the second stage of China’s nationwide vaccine rollout. Front Med 8:761601. https://doi.org/10.3389/fmed.2021.761601
doi: 10.3389/fmed.2021.761601
Tzur Bitan D (2021) Patients with schizophrenia are under-vaccinated for COVID-19: a report from Israel. World Psychiatry 20:300–301. https://doi.org/10.1002/wps.20874
doi: 10.1002/wps.20874
pubmed: 34002527
Tzur Bitan D, Kridin K, Givon-Lavi N et al (2022) COVID-19 booster vaccination among individuals with schizophrenia in Israel. JAMA Psychiatry 79:508–512. https://doi.org/10.1001/jamapsychiatry.2022.0382
doi: 10.1001/jamapsychiatry.2022.0382
pubmed: 35353114
pmcid: 8968735
Wiegand HF, Maicher B, Rueb M et al (2022) COVID-19 vaccination rates in hospitalized mentally ill patients compared to the general population in Germany—results from the COVID Ψ Vac study. Eur Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.33
doi: 10.1192/j.eurpsy.2022.33
pubmed: 35762046
pmcid: 9300974
Peritogiannis V, Drakatos I, Gioti P, Garbi A (2022) Vaccination rates against COVID-19 in patients with severe mental illness attending community mental health services in rural Greece. Int J Soc Psychiatry. https://doi.org/10.1177/00207640221081801
doi: 10.1177/00207640221081801
pubmed: 35253527
pmcid: 9936167
Lim C, Van Alphen MU, Maclaurin S et al (2022) Increasing COVID-19 vaccination rates among patients with serious mental illness: a pilot intervention study. Psychiatr Serv. https://doi.org/10.1176/appi.ps.202100702
doi: 10.1176/appi.ps.202100702
pubmed: 36196531
Mazereel V, Vanbrabant T, Desplenter F et al (2021) COVID-19 vaccination rates in a cohort study of patients with mental illness in residential and community care. Front Psychiatry 12:805528. https://doi.org/10.3389/fpsyt.2021.805528
doi: 10.3389/fpsyt.2021.805528
pubmed: 34975599
pmcid: 8716918
Mazereel V, Vanbrabant T, Desplenter F, De Hert M (2021) COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital. Lancet Psychiatry 8:860–861. https://doi.org/10.1016/S2215-0366(21)00301-1
doi: 10.1016/S2215-0366(21)00301-1
pubmed: 34416185
pmcid: 8372496
Bai W, Cai H, Jin Y et al (2021) COVID-19 vaccine hesitancy in community-dwelling and hospitalized patients with severe mental illness. Psychol Med. https://doi.org/10.1017/S0033291721004918
doi: 10.1017/S0033291721004918
pubmed: 34915962
pmcid: 9433704
Hassan L, Sawyer C, Peek N et al (2022) COVID-19 vaccination uptake in people with severe mental illness: a UK-based cohort study. World Psychiatry 21:153–154. https://doi.org/10.1002/wps.20945
doi: 10.1002/wps.20945
pubmed: 35015350
pmcid: 8751570
Eyllon M, Dang AP, Barnes BJ et al (2022) Associations between psychiatric morbidity and COVID-19 vaccine hesitancy: An analysis of electronic health records and patient survey. Psychiatry Res 307:114329. https://doi.org/10.1016/j.psychres.2021.114329
doi: 10.1016/j.psychres.2021.114329
pubmed: 34910966
Nilsson SF, Laursen TM, Osler M et al (2022) Vaccination against SARS-CoV‑2 infection among vulnerable and marginalised population groups in Denmark: a nationwide population-based study. Lancet Reg Health Eur 16:100355. https://doi.org/10.1016/j.lanepe.2022.100355
doi: 10.1016/j.lanepe.2022.100355
pubmed: 35350631
pmcid: 8948003
Hao F, Wang B, Tan W et al (2021) Attitudes toward COVID-19 vaccination and willingness to pay: comparison of people with and without mental disorders in China. BJPsych open 7:e146. https://doi.org/10.1192/bjo.2021.979
doi: 10.1192/bjo.2021.979
pubmed: 34422295
Danenberg R, Shemesh S, Bitan DT et al (2021) Attitudes of patients with severe mental illness towards COVID-19 vaccinations: A preliminary report from a public psychiatric hospital. J Psychiatr Res 143:16–20. https://doi.org/10.1016/j.jpsychires.2021.08.020
doi: 10.1016/j.jpsychires.2021.08.020
pubmed: 34438198
pmcid: 8376832
Jefsen OH, Kølbæk P, Gil Y et al (2021) COVID-19 vaccine willingness amongst patients with mental illness compared with the general population. Acta Neuropsychiatr 33:273–276. https://doi.org/10.1017/neu.2021.15
doi: 10.1017/neu.2021.15
pubmed: 33998428
Pan K‑Y, Kok AAL, Penninx BWJH, Giltay EJ (2022) Attitudes towards COVID-19 vaccination: A comparison between persons with different chronicity of pre-pandemic depressive, anxiety or obsessive-compulsive disorders. Acta Psychiatr Scand 145:412–415. https://doi.org/10.1111/acps.13399
doi: 10.1111/acps.13399
pubmed: 35263442
pmcid: 9111256
Zhao Y‑M, Liu L, Sun J et al (2021) Public willingness and determinants of COVID-19 vaccination at the initial stage of mass vaccination in China. Vaccines 9:1172. https://doi.org/10.3390/vaccines9101172
doi: 10.3390/vaccines9101172
pubmed: 34696281
pmcid: 8538840
Zheng Y‑B, Sun J, Liu L et al (2021) COVID-19 vaccine-related psychological stress among general public in China. Front Psychiatry 12:774504. https://doi.org/10.3389/fpsyt.2021.774504
doi: 10.3389/fpsyt.2021.774504
pubmed: 34950070
pmcid: 8689133
Oyekale AS (2021) Compliance indicators of COVID-19 prevention and vaccines hesitancy in Kenya: a random-effects endogenous probit model. Vaccines 9:1359. https://doi.org/10.3390/vaccines9111359
doi: 10.3390/vaccines9111359
pubmed: 34835290
pmcid: 8618705
Dalkner N, Fleischmann E, Fellendorf FT et al (2022) COVID-19 vaccination motivation and underlying believing processes: a comparison study between individuals with affective disorder and healthy controls. Front Psychol 13:935278. https://doi.org/10.3389/fpsyg.2022.935278
doi: 10.3389/fpsyg.2022.935278
pubmed: 36562048
pmcid: 9765308
Masson CL, McCuistian C, Straus E et al (2021) COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs. Drug Alcohol Depend 225:108812. https://doi.org/10.1016/j.drugalcdep.2021.108812
doi: 10.1016/j.drugalcdep.2021.108812
pubmed: 34174773
pmcid: 8221747
Haderlein TP, Steers WN, Dobalian A (2022) Serious mental illness diagnosis and COVID-19 vaccine uptake in the veterans health administration. Psychiatr Serv. https://doi.org/10.1176/appi.ps.202100499
doi: 10.1176/appi.ps.202100499
pubmed: 35042373